Latest news and press releases about Supernus Pharmaceuticals, Inc. (SUPN): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention.
Price
| Price | $42.76 |
| Market Cap | $2.5B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.41 |
| EV / EBITDA | -147.59 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -10.42% |
| Return on Invested Capital | -9.12% |
| Return on Assets | -7.69% |
| Gross Margin | 88.07% |
| Operating Margin | -13.46% |
| Net Margin | -13.23% |
Related companies: AMRX · BHC · CGON · GRAL · HCM · INDV
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of SUPN: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks